American International Group, Inc. Provention Bio, Inc. Transaction History

American International Group, Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$6.7 - $24.21 $4,060 - $14,671	606 Added 2.03%	30,446 $733,000
Q4 2022 Feb 10, 2023	BUY	$4.52 - $10.57 $8,267 - $19,332	1,829 Added 6.53%	29,840 $315,000
Q3 2022 Nov 14, 2022	BUY	$3.43 - $5.62 $6,225 - $10,200	1,815 Added 6.93%	28,011 $126,000
Q2 2022 Aug 12, 2022	SELL	$3.65 - $7.3 $4,891 - $9,782	-1,340 Reduced 4.87%	26,196 $105,000
Q1 2022 May 13, 2022	SELL	$3.4 - $7.88 $6,585 - $15,263	-1,937 Reduced 6.57%	27,536 $202,000
Q4 2021 Feb 11, 2022	SELL	$5.59 - $7.39 $4,930 - $6,517	-882 Reduced 2.91%	29,473 $166,000
Q3 2021 Nov 12, 2021	SELL	$5.66 - $8.33 $4,086 - $6,014	-722 Reduced 2.32%	30,355 $194,000
Q2 2021 Aug 13, 2021	BUY	$6.71 - $11.04 $1,013 - $1,667	151 Added 0.49%	31,077 $262,000
Q1 2021 May 07, 2021	BUY	$10.12 - $19.45 $32,950 - $63,329	3,256 Added 11.77%	30,926 $325,000
Q4 2020 Feb 12, 2021	SELL	$11.79 - $18.94 $9,349 - $15,019	-793 Reduced 2.79%	27,670 $469,000
Q3 2020 Nov 04, 2020	BUY	$10.34 - $15.2 $26,315 - $38,684	2,545 Added 9.82%	28,463 $365,000
Q2 2020 Aug 12, 2020	BUY	$7.81 - $17.0 $202,419 - $440,606	25,918 New	25,918 $366,000

170K

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

Stay updated on American International Group, Inc. with notifications on news.